| Stereochemistry | ABSOLUTE |
| Molecular Formula | C40H66N2O9 |
| Molecular Weight | 718.96 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(O[C@@H]1C[C@@](C)(O)\C=C\C=C(/C)[C@@]2([H])OC(=O)C[C@H](O)CC[C@@](C)(O)[C@@H](OC(=O)N3CCN(CC3)C4CCCCCC4)\C=C\[C@@H]2C)[C@H](C)[C@@H](O)CC
InChI
InChIKey=MNOMBFWMICHMKG-MGYWSNOQSA-N
InChI=1S/C40H66N2O9/c1-7-32(44)29(4)37-33(49-37)26-39(5,47)19-12-13-27(2)36-28(3)16-17-34(40(6,48)20-18-31(43)25-35(45)51-36)50-38(46)42-23-21-41(22-24-42)30-14-10-8-9-11-15-30/h12-13,16-17,19,28-34,36-37,43-44,47-48H,7-11,14-15,18,20-26H2,1-6H3/b17-16+,19-12+,27-13+/t28-,29+,31+,32-,33+,34-,36+,37+,39-,40+/m0/s1
| Molecular Formula | C40H66N2O9 |
| Molecular Weight | 718.96 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
E7107 is a semisynthetic derivative of the natural product pladienolide B which was originally isolated from Streptomyces platensis. E7107 is the first compound a new class of anti-cancer agents targeting the spliceosome. Specifically E7107 interacts with the Splicing factor 3B subunit 1 (SF3b1) to block the normal splicing of oncogenes. Development of E7107 was suspended after Phase I clinical trials due to an unacceptable profile of adverse events.
Originator
Approval Year
Doses
AEs
Sourcing
Sample Use Guides
Human patients with solid tumors were treated at escalating doses beginning at 0.6 mg/m^2. E7107 was received as a 30-minute intravenous infusion on Days 1 and 8 and repeating this cycle every 21 days. Selection of subsequent dose levels was performed according to accelerated design.
Route of Administration:
Intravenous